Cargando…

Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump

BACKGROUND: Treating severe forms of the acute respiratory distress syndrome and cardiac failure, extracorporeal membrane oxygenation (ECMO) has become an established therapeutic option. Neonatal or pediatric patients receiving ECMO, and patients undergoing extracorporeal CO(2) removal (ECCO(2)R) re...

Descripción completa

Detalles Bibliográficos
Autores principales: Schöps, Malte, Groß-Hardt, Sascha H., Schmitz-Rode, Thomas, Steinseifer, Ulrich, Brodie, Daniel, Clauser, Johanna C., Karagiannidis, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784380/
https://www.ncbi.nlm.nih.gov/pubmed/33402176
http://dx.doi.org/10.1186/s12967-020-02599-z
_version_ 1783632295820787712
author Schöps, Malte
Groß-Hardt, Sascha H.
Schmitz-Rode, Thomas
Steinseifer, Ulrich
Brodie, Daniel
Clauser, Johanna C.
Karagiannidis, Christian
author_facet Schöps, Malte
Groß-Hardt, Sascha H.
Schmitz-Rode, Thomas
Steinseifer, Ulrich
Brodie, Daniel
Clauser, Johanna C.
Karagiannidis, Christian
author_sort Schöps, Malte
collection PubMed
description BACKGROUND: Treating severe forms of the acute respiratory distress syndrome and cardiac failure, extracorporeal membrane oxygenation (ECMO) has become an established therapeutic option. Neonatal or pediatric patients receiving ECMO, and patients undergoing extracorporeal CO(2) removal (ECCO(2)R) represent low-flow applications of the technology, requiring lower blood flow than conventional ECMO. Centrifugal blood pumps as a core element of modern ECMO therapy present favorable operating characteristics in the high blood flow range (4 L/min–8 L/min). However, during low-flow applications in the range of 0.5 L/min–2 L/min, adverse events such as increased hemolysis, platelet activation and bleeding complications are reported frequently. METHODS: In this study, the hemolysis of the centrifugal pump DP3 is evaluated both in vitro and in silico, comparing the low-flow operation at 1 L/min to the high-flow operation at 4 L/min. RESULTS: Increased hemolysis occurs at low-flow, both in vitro and in silico. The in-vitro experiments present a sixfold higher relative increased hemolysis at low-flow. Compared to high-flow operation, a more than 3.5-fold increase in blood recirculation within the pump head can be observed in the low-flow range in silico. CONCLUSIONS: This study highlights the underappreciated hemolysis in centrifugal pumps within the low-flow range, i.e. during pediatric ECMO or ECCO(2)R treatment. The in-vitro results of hemolysis and the in-silico computational fluid dynamic simulations of flow paths within the pumps raise awareness about blood damage that occurs when using centrifugal pumps at low-flow operating points. These findings underline the urgent need for a specific pump optimized for low-flow treatment. Due to the inherent problems of available centrifugal pumps in the low-flow range, clinicians should use the current centrifugal pumps with caution, alternatively other pumping principles such as positive displacement pumps may be discussed in the future. [Image: see text]
format Online
Article
Text
id pubmed-7784380
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77843802021-01-14 Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump Schöps, Malte Groß-Hardt, Sascha H. Schmitz-Rode, Thomas Steinseifer, Ulrich Brodie, Daniel Clauser, Johanna C. Karagiannidis, Christian J Transl Med Research BACKGROUND: Treating severe forms of the acute respiratory distress syndrome and cardiac failure, extracorporeal membrane oxygenation (ECMO) has become an established therapeutic option. Neonatal or pediatric patients receiving ECMO, and patients undergoing extracorporeal CO(2) removal (ECCO(2)R) represent low-flow applications of the technology, requiring lower blood flow than conventional ECMO. Centrifugal blood pumps as a core element of modern ECMO therapy present favorable operating characteristics in the high blood flow range (4 L/min–8 L/min). However, during low-flow applications in the range of 0.5 L/min–2 L/min, adverse events such as increased hemolysis, platelet activation and bleeding complications are reported frequently. METHODS: In this study, the hemolysis of the centrifugal pump DP3 is evaluated both in vitro and in silico, comparing the low-flow operation at 1 L/min to the high-flow operation at 4 L/min. RESULTS: Increased hemolysis occurs at low-flow, both in vitro and in silico. The in-vitro experiments present a sixfold higher relative increased hemolysis at low-flow. Compared to high-flow operation, a more than 3.5-fold increase in blood recirculation within the pump head can be observed in the low-flow range in silico. CONCLUSIONS: This study highlights the underappreciated hemolysis in centrifugal pumps within the low-flow range, i.e. during pediatric ECMO or ECCO(2)R treatment. The in-vitro results of hemolysis and the in-silico computational fluid dynamic simulations of flow paths within the pumps raise awareness about blood damage that occurs when using centrifugal pumps at low-flow operating points. These findings underline the urgent need for a specific pump optimized for low-flow treatment. Due to the inherent problems of available centrifugal pumps in the low-flow range, clinicians should use the current centrifugal pumps with caution, alternatively other pumping principles such as positive displacement pumps may be discussed in the future. [Image: see text] BioMed Central 2021-01-05 /pmc/articles/PMC7784380/ /pubmed/33402176 http://dx.doi.org/10.1186/s12967-020-02599-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Schöps, Malte
Groß-Hardt, Sascha H.
Schmitz-Rode, Thomas
Steinseifer, Ulrich
Brodie, Daniel
Clauser, Johanna C.
Karagiannidis, Christian
Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
title Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
title_full Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
title_fullStr Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
title_full_unstemmed Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
title_short Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
title_sort hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784380/
https://www.ncbi.nlm.nih.gov/pubmed/33402176
http://dx.doi.org/10.1186/s12967-020-02599-z
work_keys_str_mv AT schopsmalte hemolysisatlowbloodflowratesinvitroandinsilicoevaluationofacentrifugalbloodpump
AT großhardtsaschah hemolysisatlowbloodflowratesinvitroandinsilicoevaluationofacentrifugalbloodpump
AT schmitzrodethomas hemolysisatlowbloodflowratesinvitroandinsilicoevaluationofacentrifugalbloodpump
AT steinseiferulrich hemolysisatlowbloodflowratesinvitroandinsilicoevaluationofacentrifugalbloodpump
AT brodiedaniel hemolysisatlowbloodflowratesinvitroandinsilicoevaluationofacentrifugalbloodpump
AT clauserjohannac hemolysisatlowbloodflowratesinvitroandinsilicoevaluationofacentrifugalbloodpump
AT karagiannidischristian hemolysisatlowbloodflowratesinvitroandinsilicoevaluationofacentrifugalbloodpump